Immutep Ltd (PRRUF) Price & Analysis

Compare

25 Followers

PRRUF Stock Chart & Stats

$0.25

$0.00(0.00%)

At close: Nov 12 4:00 PM EST

$0.25

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.18 - $0.33

Previous CloseN/A

Volume70.00

Average Volume (3M)1.42K

Market Cap

$402.46M

Enterprise Value$496.10M

Total Cash (Recent Filing)$99.13M

Total Debt (Recent Filing)$2.16M

Price to Earnings (P/E)―

Beta0.24

Next Earnings

Sep 02, 2026

EPS Estimate

-0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding1,473,721,300

10 Day Avg. Volume4,000

30 Day Avg. Volume1,416

Financial Highlights & Ratios

PEG Ratio-0.31

Price to Book (P/B)2.43

Price to Sales (P/S)69.27

P/FCF Ratio-5.63

Enterprise Value/Market Cap1.23

Enterprise Value/Revenue83.01

Enterprise Value/Gross Profit-15.88

Enterprise Value/Ebitda-5.95

Forecast

1Y Price Target

$0.80

Price Target Upside221.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.03

Revenue Forecast (FY)$18.91M

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Equity PositionConservative leverage and a healthy equity base reduce refinancing and bankruptcy risk, giving management flexibility to fund R&D and clinical programs without immediate debt pressures. This structural strength supports long-term investment in trials and partnership negotiations.

Improving Free Cash Flow GrowthAn improvement in free cash flow growth indicates progress toward better cash conversion from operations. If sustained, this trend can lengthen runway, lower reliance on dilutive capital raises and improve the company's ability to fund later-stage trials or execute partnerships without urgent financing.

Proprietary LAG-3 Platform And Clinical PipelineOwning a differentiated LAG-3 research platform and an advancing clinical asset (efti) represents a durable competitive advantage: platform science can generate multiple programs, attract partnerships, and deliver long-term value if clinical and regulatory milestones are met.

Bears Say

Persistent Losses And Negative Cash FlowsSustained operating losses and negative cash flows erode financial flexibility and necessitate ongoing external funding. Over months this increases execution risk, can delay programs, and raises the probability of dilutive capital raises that impact long-term shareholder value.

Negative Margins And Operational InefficiencyBroad negative margins reflect persistent cost structures that are not yet scalable. Continued operational inefficiency increases the capital required to reach commercialization and makes the company a less attractive partner or acquirer unless efficiency or clinical value significantly improves.

Dependence On External Funding And PartnershipsAs a clinical-stage biotech without product sales, Immutep must rely on partnerships, grants and equity raises to fund development. This structural dependency creates execution and dilution risks, and program continuity hinges on securing milestone-based deals or fresh capital.

Immutep Ltd News

Immutep initiated with an Outperform at Citizens

Citizens initiated coverage of Immutep (IMMP) with an Outperform rating and $6 price target The firm says the...

14d ago

IMMP

Immutep achieves 50% enrollment in global TACTI-004 Phase III trial

Immutep (IMMP) announces it has achieved 50% of the patient enrolment target in the TACTI-004 Phase III trial...

25d ago

IMMP

Immutep Doubles Half-Year Loss as R&D Spend Surges Despite New Collaboration Revenue

The latest update is out from Immutep Ltd ( ($AU:IMM) ). Immutep reported a net loss after tax...

6d ago

Immutep Hits 50% Enrolment Milestone in Global Phase III Lung Cancer Trial

An announcement from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep has reached 50% patient enrolment in...

26d ago

Immutep reports Q2 cash receipts from customers A$4,000

The company said, “During the quarter, Immutep (IMMP) continued to exercise prudent cash management as it advanced its...

1M ago

IMMP

Immutep Secures Dr. Reddy’s Partnership and Strengthens Clinical, Financial Position

Immutep Ltd ( ($AU:IMM) ) has provided an update. Immutep reported a pivotal quarter marked by a strategic...

1M ago

Immutep announces update on IMP761 from Phase I study

Immutep (IMMP) Limited announces a positive update from the placebo-controlled, double-blind first-in-human Phase I study in healthy participants...

2M ago

IMMP

Immutep Reports Promising Phase I Data for First-in-Class Autoimmune Antibody IMP761

An announcement from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep reported encouraging interim data from a...

2M ago

Immutep announces progress in global TACTI-004 Phase III, enrollment continues

Immutep (IMMP) reports strong operational progress in the TACTI-004 Phase III trial evaluating eftilagimod alfa in combination with...

3M ago

MRK

IMMP

Immutep Advances Global Phase III Trial for Lung Cancer Therapy

Immutep Ltd ( ($AU:IMM) ) just unveiled an announcement. Immutep Limited has announced significant progress in its global...

3M ago

Immutep’s Strategic Partnership with Dr. Reddy’s Fuels Growth Potential and Strengthens Financial Position

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Immutep and keeping the price target at...

3M ago

IMMP

Midday Fly By: IBM to buy Confluent, Paramount goes hostile for Warner Bros.

The major averages were lower near noon as markets brace for the Federal Reserve’s rate-decision later this week....

3M ago

Immutep, Dr Reddy’s enters strategic collaboration for Eftilagimod Alfa

Immutep (IMMP) and Dr. Reddy’s Laboratories (RDY) announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr. Reddy’s...

3M ago

RDY

IMMP

Immutep and Dr. Reddy’s Forge Strategic Partnership for Global Oncology Drug Commercialization

An update from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep Limited has entered into a strategic...

3M ago

PRRUF FAQ

What was Immutep Ltd’s price range in the past 12 months?

Immutep Ltd lowest stock price was $0.18 and its highest was $0.33 in the past 12 months.

What is Immutep Ltd’s market cap?

Immutep Ltd’s market cap is $402.46M.

When is Immutep Ltd’s upcoming earnings report date?

Immutep Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 183 days.

How were Immutep Ltd’s earnings last quarter?

Immutep Ltd released its earnings results on Aug 29, 2025. The company reported -$0.021 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.001.

Is Immutep Ltd overvalued?

According to Wall Street analysts Immutep Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immutep Ltd pay dividends?

Immutep Ltd does not currently pay dividends.

What is Immutep Ltd’s EPS estimate?

Immutep Ltd’s EPS estimate is -0.02.

How many shares outstanding does Immutep Ltd have?

Immutep Ltd has 1,473,721,300 shares outstanding.

What happened to Immutep Ltd’s price movement after its last earnings report?

Immutep Ltd reported an EPS of -$0.021 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Immutep Ltd?

Currently, no hedge funds are holding shares in PRRUF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Immutep Ltd Stock Smart Score

Outperform

Fundamentals

Return on Equity

-35.86%

Trailing 12-Months

Asset Growth

-23.58%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immutep Ltd

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.

Immutep Ltd (PRRUF) Earnings & Revenues

Historic Earnings Reports

PRRUF Stock 12 Month Forecast

Average Price Target

$0.80

▲(221.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.058715,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.8046234,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.45877650000000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.46</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.321,0.3777473076923077,0.4344946153846154,0.4912419230769231,0.5479892307692308,0.6047365384615385,0.6614838461538461,0.7182311538461539,0.7749784615384616,0.8317257692307694,0.8884730769230771,0.9452203846153848,1.0019676923076923,{"y":1.058715,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.321,0.3582018,0.3954036,0.43260540000000003,0.4698072,0.507009,0.5442108,0.5814126,0.6186144,0.6558162000000001,0.693018,0.7302198,0.7674216,{"y":0.8046234,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.321,0.33159819230769233,0.34219638461538465,0.3527945769230769,0.36339276923076924,0.37399096153846156,0.3845891538461539,0.3951873461538462,0.4057855384615385,0.4163837307692308,0.4269819230769231,0.4375801153846154,0.4481783076923077,{"y":0.45877650000000003,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.209,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.225,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.211,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.194,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.194,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.194,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.194,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.194,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.201,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.18,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.321,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 54, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >